Frankfurt
13.04.26 | 09:24
0,051 Euro
+3,25 % +0,002
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ISOFOL MEDICAL Aktie jetzt für 0€ handeln | |||||
| 18.03. | Isofol Medical AB: Isofol secures license rights for arfolitixorin in autism | 1.125 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, March 18, 2026 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that the company has expanded its global exclusive license agreement for arfolitixorin to also... ► Artikel lesen | |
| 11.03. | Isofol Medical AB: Isofol receives top guarantee commitment and letters of intent corresponding to 42 percent of upcoming warrant exercise | 235 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, 11 March 2026 - Isofol Medical AB ("Isofol" or the "Company") announces today that the Company has received a top guarantee commitment from existing shareholder Solasia Pharma K.K.... ► Artikel lesen | |
| 24.02. | Isofol Medical AB: Isofol provides update on the ongoing phase Ib/II clinical study of arfolitixorin | 258 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, February 24, 2026 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today provides an update on the company's ongoing phase Ib/II clinical study of arfolitixorin, which is initially... ► Artikel lesen | |
| 18.02. | Isofol Medical AB: Isofol Medical AB (publ) publishes year-end report, January - December 2025 | 126 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, February 18, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), ("Isofol" or the "Company"), announced today that the company's year-end report for January - December 2025... ► Artikel lesen | |
| 13.11.25 | Isofol Medical AB: European Patent Office intends to grant a new patent for Isofol's arfolitixorin | 226 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, November 13 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the European Patent Office (EPO) has issued an Intention to Grant notice regarding a... ► Artikel lesen | |
| 12.11.25 | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-September 2025 | 205 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, November 12, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), ("Isofol" or the "Company"), announced today that the company's interim report for January-September 2025... ► Artikel lesen | |
| 30.09.25 | Isofol Medical AB: Isofol's clinical study with arfolitixorin reaches another important milestone | 377 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, September 30, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has successfully completed the second dose level in the dose escalating... ► Artikel lesen | |
| 26.09.25 | Isofol Medical AB: Isofol completes transfer of shares to Solasia Pharma following a successful rights issue | 262 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, September 26, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the transfer of the shares subscribed by the Japanese collaboration partner Solasia... ► Artikel lesen | |
| 26.08.25 | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-June 2025 | 210 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, August 26, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January-June 2025 is now available, in Swedish, on the... ► Artikel lesen | |
| 16.07.25 | Isofol Medical AB: Isofol successfully completes pre-IND meeting with the FDA for arfolitixorin | 297 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, July 16, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has successfully completed a pre-IND meeting with the U.S. Food and Drug Administration... ► Artikel lesen | |
| 12.06.25 | Isofol Medical AB: Isofol completes first cohort in ongoing clinical study with arfolitixorin | 390 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, June 12, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has completed the first cohort in the ongoing phase Ib/II clinical study with... ► Artikel lesen | |
| 12.06.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.06.2025 | 527 | Xetra Newsboard | Das Instrument W1E JE00BSBJ5M88 ROSEBANK INDS LS -,001 EQUITY wird ex Kapitalmassnahme gehandelt am 12.06.2025 The instrument W1E JE00BSBJ5M88 ROSEBANK INDS LS -,001 EQUITY is traded ex capital adjustment... ► Artikel lesen | |
| 11.06.25 | Isofol Medical AB: Bulletin from extraordinary general meeting in Isofol Medical AB (publ) held on 11 June 2025 | 260 | GlobeNewswire (Europe) | GOTHENBURG, 11 June 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), held its extra ordinary general meeting today at which the following main resolutions were passed by the shareholders.
The... ► Artikel lesen | |
| 05.06.25 | Isofol Medical AB: Isofol announces final terms of the rights issue and the potential overallotment issue | 319 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, 5 June 2025 - The Board of Directors of Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) ("Isofol" or the "Company") announced on 12 May 2025, that the Board of Directors, subject... ► Artikel lesen | |
| 21.05.25 | Isofol Medical AB: Isofol Medical AB (publ) publishes Interim report, January - March 2025 | 232 | GlobeNewswire (Europe) | GOTHENBURG, Sweden, May 21, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January - March 2025 is now available on the company's... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,657 | -1,52 % | Valneva im freien Fall: Warum erfahrene Anleger heute die Reißleine ziehen - Meine klare Einschätzung dazu | ||
| INTELLIA THERAPEUTICS | 12,260 | +6,42 % | Intellia Therapeutics, Inc. - 8-K, Current Report | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,181 | +2,92 % | PacBio Announces the Appointment of Chris Gibson to the Board of Directors | MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,202 | +1,69 % | Cardiol Therapeutics Inc. - 6-K, Report of foreign issuer | ||
| ATAIBECKLEY | 3,220 | +3,87 % | Analysten schwärmen nur so: Ataibeckley: Nur Kaufempfehlungen - Potenzial von 200 bis 500 Prozent! | © Foto: DALL-E Jeder Anleger ist auf der Suche nach der Aktie, die im Depot explodiert. Für eine solche Entwicklung müssen Investoren früh an Bord gehen. Ataibeckley könnte so ein Papier sein, dass... ► Artikel lesen | |
| BIOMERIEUX | 90,90 | +0,83 % | BioMerieux SA Profit Declines In Full Year | PARIS (dpa-AFX) - BioMerieux SA (EYWN.MU) reported earnings for full year that Drops, from the same period last yearThe company's bottom line totaled EUR397.5 million, or EUR3.34 per share.... ► Artikel lesen | |
| BIO GREEN MED SOLUTION | 1,030 | +3,50 % | Bio Green Med Solution kündigt Quartalsdividende für Vorzugsaktien an | ||
| ANAPTYSBIO | 58,78 | +1,59 % | AnaptysBio, Inc.: First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement | Inclusive of $80 million in proceeds from private placement by leading investorsFirst Tracks Biotherapeutics to launch with $180 million in cash and two-year cash-runway SAN DIEGO, March 27, 2026... ► Artikel lesen | |
| GENUS | 30,000 | +2,04 % | Genus PLC - Director/PDMR Shareholding | ||
| ABIONYX PHARMA | 3,605 | +0,14 % | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| MEIRAGTX | 7,800 | +1,96 % | MeiraGTx Reports Third Quarter 2025 Financial and Operational Results | Entered into broad strategic collaboration with Eli Lilly and Company ("Lilly") in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company's AAV-AIPL1 program for treatment... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 1,830 | -1,61 % | XFRA HHB0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| AKESO | 15,195 | +2,01 % | Akeso, Inc.: Akeso Reports Full-Year 2025 Financial Results | HONG KONG, March 26, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2025 annual results, highlighting a year of comprehensive... ► Artikel lesen | |
| MAAT PHARMA | 5,400 | -5,92 % | MaaT Pharma Announces Publication of Retrospective Data in Third-Line Acute GvHD from the CHRONOS Study in Bone Marrow Transplantation Journal | CHRONOS is one of the largest real-world studies including refractory GI-aGvHD patients (n=59) treated with third-line best available treatments other than microbiome-based therapy
Results... ► Artikel lesen | |
| QIAGEN | 35,350 | +0,91 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen |
ISOFOL MEDICAL AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,002 (+3,25 %) liegt der Kurs bei 0,051 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ISOFOL MEDICAL AB finden Sie auf Wallstreet Online.